Gainers
- Cidara Therapeutics CDTX stock moved upwards by 14.1% to $0.91 during Thursday's after-market session. The company's market cap stands at $60.6 million.
- Biophytis BPTS shares increased by 6.99% to $4.74. The market value of their outstanding shares is at $61.1 million.
- Spectrum Pharmaceuticals SPPI stock increased by 6.74% to $0.67. The market value of their outstanding shares is at $117.8 million.
- Trevena TRVN shares rose 5.0% to $0.5. The market value of their outstanding shares is at $82.9 million.
- Ortho Clinical Diagnostic OCDX shares increased by 4.96% to $18.16. Ortho Clinical Diagnostic's trading volume hit 207.1K shares by close, accounting for 14.3% of its average volume over the last 100 days. The company's market cap stands at $4.3 billion.
- Provention Bio PRVB stock rose 4.95% to $5.3. This security traded at a volume of 75.9K shares come close, making up 7.3% of its average volume over the last 100 days. The company's market cap stands at $335.8 million.
Losers
- Lannett LCI shares fell 20.6% to $1.14 during Thursday's after-market session. This security traded at a volume of 69.6K shares come close, making up 14.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $49.3 million. As per the press release, Q2 earnings came out today.
- Syros Pharmaceuticals SYRS shares decreased by 2.8% to $1.74. The company's market cap stands at $107.7 million.
- Pasithea Therapeutics KTTA stock fell 2.57% to $1.14. The company's market cap stands at $24.9 million.
- Aridis Pharmaceuticals ARDS shares declined by 2.39% to $2.05. The company's market cap stands at $28.8 million.
- OpGen OPGN stock declined by 2.19% to $0.87. The company's market cap stands at $40.4 million.
- Epizyme EPZM stock decreased by 2.18% to $1.35. The market value of their outstanding shares is at $219.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in